33 results about "Roseburia" patented technology

The present invention relates to Roseburia flagellin, and / or a polynucleotide sequence encoding said Roseburia flagellin, and / or a vector comprising said polynucleotide sequence, and / or a host cell, including bacteria, comprising said vector, and / or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and are also encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced.

A method for treating an individual suffering from one of bladder cancer and colorectal cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. Still other embodiments include increasing the levels of Roseburia and / or Faecalibacterium prausnitzii, in the individual's gut microbiome.

A person's intestinal (gut), oral or skin microbiota is modified using specific combinations of pre-biotics, pro-biotics and / or anti-biotics to establish a defined microbiota that can treat and / or reduce the likelihood that individuals will experience various diseases, including cancer. The employment of various bacteria, whether in particular combinations or after being modified using CRISPR-type systems, leads to improved outcomes when checkpoint inhibitors are used to treat various forms of cancer. One embodiment is directed to a method for reducing the likelihood of developing cancer by providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species. The level of Roseburia and Faecalibacterium prausnitzii, and / or Akkermansia muciniphila bacteria are increased in the individual's gut microbiome such that when an individual is administered an immune checkpoint inhibitor, its function is enhanced due to the presence of the bacterial population.

The disclosure relates generally to bacterial strains and bacterial strain mixtures, e.g., Eubacterium, Bacteroides, and Roseburia bacterial strains and mixtures thereof. The disclosure further relates to methods of using bacterial strains and bacterial strain mixtures for treating a gastrointestinal disorder, e.g, ulcerative colitis, an inflammatory disorder, and / or dysbiosis.

The invention belongs to the field of life sciences, and in particular relates to the new application of Roseburia in preventing and treating anxiety and depression. The invention provides the application of Roseburia in preparing medicines for preventing and treating anxiety and depression. The consumption of described Roseburia (Roseburia) viable bacteria is every day 1 * 10 4 -1×10 20 CFU / mL.

The present disclosure provides a use of Roseburia in the preparation of composition for prevention and / or treatment of obesity related diseases. Also provided are a composition used in the treatment and prevention for obesity related diseases, comprising pharmaceutical, drink, food, or animal feed composition, etc; and a method of reducing body weight and / or blood glucose.

A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease involves providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species, and administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual. In certain embodiments, monoacylglycerolacyltransferase-3 (MGAT3) synthesis is inhibited to lower triacylglycerol (TAG) production, while in others, expression of diacylglycerolacyltransferase-2 (DGAT-2) is inhibited. The beneficial bacteria are preferably modified to produce increased amounts of butyrate and may also be encapsulated in a frangible enclosure. Levels of Roseburia are preferably increased while the levels of Akkermansia spp. in the individual's gut microbiome are reduced. In other embodiments, a therapeutically effective amount of a bacterial formulation comprising Faecalibacterium prausnitzii is administered, or a composition comprising modified L. reuteri bacteria having the ability to survive conditions in the duodenum or jejunum of the individual's small intestine. Other embodiments include the administration of a bacterial formulation comprising at least one of Coprococcus, Veillonella, Roseburia, Bifidobacterium, Faecalibacterium prausnitzii and Prevotella.

The present invention provides a method, wherein the method treats a subject having a dysbiosis, the method comprising: determining a first metabolic profile of the gut microbiome of a subject having a dysbiosis; changing the first metabolic profile of the gut microbiome of the subject to a second metabolic profile of the gut microbiome of the subject, by administering to the subject a composition comprising at least one bacterial species selected from the group consisting of: Acidaminococcus intestinalis, Bacteroides ovatus, Bifidobacterium adolescentis, Bifidobacterium longum, Blautia sp., Clostridium sp., Collinsella aerofaciens, Escherichia coli, Eubacterium desmolans, Eubacterium eligens, Eubacterium limosum, Faecalibacterum prausnitzii, Lachnospira pectinoschiza, Lactobacillus casei, Parabacteroides distasonis, Roseburia faecalis, Roseburia intestinalis, Ruminococcus sp., Ruminococcus species, and Ruminococcus torques, wherein the composition is administered at a therapeutically effective amount, sufficient to alter the first metabolic profile of the gut microbiome to the second metabolic profile of the gut microbiome.